Palmitoyl acyltransferase Aph2 in cardiac function and the development of cardiomyopathy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 51, 2015, Pages 15666-15671

  Zhou, Tielin ^a,b   Li, Jing ^a   Zhao, Peiquan ^a   Liu, Huijuan ^a   Jia, Deyong ^b   Jia, Hao ^a   He, Lin ^a   Cang, Yong ^c,d   Boast, Sharon ^c,e   Chen, Yi Han ^f   Thibault, Hélène ^g   Scherrer Crosbie, Marielle ^g   Goff, Stephen P ^c   Li, Baojie ^a,f  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c New York Presbyterian Columbia University Medical Center   (United States)

^d ZHEJIANG UNIVERSITY   (China)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Aph2 gene; Cardiac development; Eye development; Palmitoyl transferase; Phospholamban

Indexed keywords

CYSTEINE; DIACYLGLYCEROL ACYLTRANSFERASE 2; PHOSPHOLAMBAN; PHOSPHOPROTEIN PHOSPHATASE 1; SERINE; ACYLTRANSFERASE; CALCIUM BINDING PROTEIN; CARRIER PROTEIN; ZDHHC16 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; EMBRYO; EYE DEVELOPMENT; HEART DEVELOPMENT; HEART FUNCTION; HISTOPATHOLOGY; MOUSE; NEWBORN; NONHUMAN; PALMITOYLATION; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; ANIMAL; CARDIOMYOPATHIES; CHLOROCEBUS AETHIOPS; COS CELL LINE; ECHOCARDIOGRAPHY; EMBRYOLOGY; EYE; LIPOYLATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ACYLTRANSFERASES; ANIMALS; CALCIUM-BINDING PROTEINS; CARDIOMYOPATHIES; CARRIER PROTEINS; CERCOPITHECUS AETHIOPS; COS CELLS; ECHOCARDIOGRAPHY; EYE; LIPOYLATION; MICE; PHOSPHORYLATION;

EID: 84952684863     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1518368112     Document Type: Article

References (43)

1. Resh MD (2006) Palmitoylation of ligands, receptors, and intracellular signaling molecules. Sci STKE 2006(359): re14.
2. Linder ME, Deschenes RJ (2007) Palmitoylation: Policing protein stability and traffic. Nat Rev Mol Cell Biol 8(1):74-84.
3. Greaves J, Carmichael JA, Chamberlain LH (2011) The palmitoyl transferase DHHC2 targets a dynamic membrane cycling pathway: Regulation by a C-terminal domain. Mol Biol Cell 22(11):1887-1895.
4. Greaves J, Chamberlain LH (2011) DHHC palmitoyl transferases: Substrate interactions and (patho) physiology. Trends Biochem Sci 36(5):245-253.
5. Fukata Y, Fukata M (2010) Protein palmitoylation in neuronal development and synaptic plasticity. Nat Rev Neurosci 11(3):161-175.
6. Mill P, et al. (2009) Palmitoylation regulates epidermal homeostasis and hair follicle differentiation. PLoS Genet 5(11):e1000748.
7. Oh Y, et al. (2012) Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cells. Cell Death Differ 19(7):1196-1207.
8. Thomas GM, Hayashi T, Chiu SL, Chen CM, Huganir RL (2012) Palmitoylation by DHHC5/8 targets GRIP1 to dendritic endosomes to regulate AMPA-R trafficking. Neuron 73(3):482-496.
9. Saleem AN, et al. (2010) Mice with alopecia, osteoporosis, and systemic amyloidosis due to mutation in Zdhhc13, a gene coding for palmitoyl acyltransferase. PLoS Genet 6(6):e1000985.
10. Linder ME, Deschenes RJ (2004) Model organisms lead the way to protein palmitoyltransferases. J Cell Sci 117(Pt 4):521-526.
11. Roth AF, et al. (2006) Global analysis of protein palmitoylation in yeast. Cell 125(5):1003-1013.
12. Kaye DM, Hoshijima M, Chien KR (2008) Reversing advanced heart failure by targeting Ca2+ cycling. Annu Rev Med 59:13-28.
13. Wehrens XH, Lehnart SE, Marks AR (2005) Intracellular calcium release and cardiac disease. Annu Rev Physiol 67:69-98.
14. MacLennan DH, Kranias EG (2003) Phospholamban: A crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 4(7):566-577.
15. Ahmad F, Seidman JG, Seidman CE (2005) The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet 6:185-216.
16. Chu G, Kranias EG (2006) Phospholamban as a therapeutic modality in heart failure. Novartis Found Symp 274:156-171, discussion 172-175, 272-276.
17. Freedman NJ, Lefkowitz RJ (2004) Anti-beta (1)-adrenergic receptor antibodies and heart failure: Causation, not just correlation. J Clin Invest 113(10):1379-1382.
18. Aoyama H, et al. (2011) Isoform-specific roles of protein phosphatase 1 catalytic subunits in sarcoplasmic reticulum-mediated Ca (2+) cycling. Cardiovasc Res 89(1):79-88.
19. Qian J, et al. (2011) Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling. Circ Res 108(12):1429-1438.
20. Howie J, et al. (2014) Substrate recognition by the cell surface palmitoyl transferase DHHC5. Proc Natl Acad Sci USA 111(49):17534-17539.
21. Zuckerman DM, Hicks SW, Charron G, Hang HC, Machamer CE (2011) Differential regulation of two palmitoylation sites in the cytoplasmic tail of the beta1-adrenergic receptor. J Biol Chem 286(21):19014-19023.
22. Lin MJ, et al. (2013) Massive palmitoylation-dependent endocytosis during reoxygenation of anoxic cardiac muscle. eLife 2:e01295.
23. Li B, Cong F, Tan CP, Wang SX, Goff SP (2002) Aph2, a protein with a zf-DHHC motif, interacts with c-Abl and has pro-apoptotic activity. J Biol Chem 277(32):28870-28876.
24. Whelan RS, Kaplinskiy V, Kitsis RN (2010) Cell death in the pathogenesis of heart disease: Mechanisms and significance. Annu Rev Physiol 72:19-44.
25. Whelan RS, Konstantinidis K, Xiao RP, Kitsis RN (2013) Cardiomyocyte life-death decisions in response to chronic β-adrenergic signaling. Circ Res 112(3):408-410.
26. Olson EN (2006) Gene regulatory networks in the evolution and development of the heart. Science 313(5795):1922-1927.
27. Molkentin JD (2004) Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 63(3):467-475.
28. Depre C, et al. (1998) Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med 4(11):1269-1275.
29. Chen Z, Akin BL, Jones LR (2007) Mechanism of reversal of phospholamban inhibition of the cardiac Ca2+-ATPase by protein kinase A and by anti-phospholamban monoclonal antibody 2D12. J Biol Chem 282(29):20968-20976.
30. Schmitt JP, et al. (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299(5611):1410-1413.
31. Moffett S, et al. (1996) Palmitoylated cysteine 341 modulates phosphorylation of the beta2-adrenergic receptor by the cAMP-dependent protein kinase. J Biol Chem 271(35):21490-21497.
32. Maruyama K, MacLennan DH (1988) Mutation of aspartic acid-351, lysine-352, and lysine-515 alters the Ca2+ transport activity of the Ca2+-ATPase expressed in COS-1 cells. Proc Natl Acad Sci USA 85(10):3314-3318.
33. Luo W, et al. (1994) Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 75(3):401-409.
34. Song Q, et al. (2003) Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest 111(6):859-867.
35. Sato Y, et al. (2001) Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem 276(12):9392-9399.
36. Zhang T, et al. (2010) Phospholamban ablation rescues sarcoplasmic reticulum Ca (2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta (C) transgenic mice. Circ Res 106(2):354-362.
37. Janczewski AM, et al. (2004) Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model. Cardiovasc Res 62(3):468-480.
38. Qiu Z, Cang Y, Goff SP (2010) c-Abl tyrosine kinase regulates cardiac growth and development. Proc Natl Acad Sci USA 107(3):1136-1141.
39. Kerkelä R, et al. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12(8):908-916.
40. Haghighi K, et al. (2006) A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci USA 103(5):1388-1393.
41. De Witt MM, MacLeod HM, Soliven B, McNally EM (2006) Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J Am Coll Cardiol 48(7):1396-1398.
42. Haghighi K, et al. (2003) Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 111(6):869-876.
43. Committee on Care and Use of Laboratory Animals (1996) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85-23.